Click Therapeutics

Yesterday, at DTx West, the pharma giant and the DTx company sat down to discuss implementing DTx for mental illness.

The randomized controlled trial of the jointly-developed digital therapeutics will be conducted using Verily's Project Baseline and enroll up to 540 patients. 

MobiHealthNews spoke with Pear Therapeutics, Click Therapeutics and DTx newcomer Mahana Therapeutics to discuss whether in-licensing is the way to go for those just entering the space.

Also: The U.S. Government Accountability Office and the National Academy of Medicine outline policy options for healthcare AI; Click Therapeutics secures $30M in debt financing.

Efficient distribution, dissipating stigma and an emphasis on decentralized trials are all working in favor of digital treatments, according to a panel of digital therapeutics executives and industry stakeholders.

The companies will be collaborating on a prescription digital therapeutic for patients with schizophrenia built on Click Therapeutics' tech platform.

Stakeholders at today's DTx East event in Boston discuss digital therapeutic risk assessment and management. 

Otsuka intends to invest more than $300 million in an FDA-cleared software app that will apply cognitive therapy principals either with or without prescription drugs.